One in three people will face a brain disorder in their lifetime, and treating brain injury and disease costs the United States $1.5 trillion every year. That is the framing the US National Institutes of Health chose for the public announcement on 15 May 2026 of its 10-year Neuroscience Research Roadmap, in a joint Director’s Message from John Ngai (Director of the NIH BRAIN Initiative) and Amy Bany Adams (Acting Director of the National Institute of Neurological Disorders and Stroke), and a formal paper in the journal Neuron. The roadmap framework itself was finalised by the BRAIN Initiative in August 2025 and organises the next decade of US federally-funded neuroscience research around four interconnected Innovation Domains.

The four Innovation Domains

The first domain is the BRAIN Knowledgebase, designed to accelerate neuroscience discovery through integrated knowledge management across four interrelated knowledgebases: the BRAIN Data Commons, the BICAN Brain Cell-Atlas Knowledgebase, the CONNECTS Knowledgebase, and the BBQS Knowledgebase. The infrastructure already spans nine federated archives holding approximately 12 petabytes of data, with BICAN alone covering roughly 100 petabytes of cell atlas data across five archives. The Knowledgebase work consolidates these existing resources around common metadata standards (NWB, BIDS) and tiered access controls rather than replacing them.

The second domain is Precision Molecular Circuit Therapies, focused on identifying and targeting specific networks of brain cells using genetic delivery systems and engineered control of neural activity. The Roadmap names “optogenetic and chemogenetic receptors” explicitly as the effector technologies, with applied examples spanning retinal blinding diseases in humans and Parkinson’s disease in preclinical work. The domain calls for proactive engagement with the FDA to identify regulatory science gaps and notes that “substantial downstream investment from industry and others will be required” to translate early-stage technology development into clinical therapy.

The third domain, Accelerating Human Neuroscience, is the bench-to-bedside translation layer. The Roadmap describes its three sub-goals as reciprocal application of circuit insights between non-human animal models and humans, advancing invasive and non-invasive measurement methods, and identifying new neuromodulation targets. The domain explicitly designs for handoffs to NIH institute-specific funding mechanisms and to external partners in the private and public sectors after first-in-human and early-feasibility studies.

The fourth domain is BRAIN NeuroAI, framed by the Roadmap as advancing “both neuroscience and artificial intelligence (AI) through bidirectional advances and knowledge exchange.” The implementation is phased: Phase 1 consists of thematic data challenges, cross-disciplinary seed grants, and supplements to existing BRAIN Initiative awards; Phase 2 introduces community benchmarking; Phase 3 expands to cooperative agreements and public-private partnerships. An annual NeuroAI summit, periodic hackathons, and a June 2025 federal roundtable round out the engagement architecture. NeuroAI’s status as a named Innovation Domain at the federal research-strategy level is the most editorially significant element of the framework. The federal government is formally treating brain-AI bidirectional research as a strategic priority, not an emerging adjacency.

How it lands against the international map

The roadmap arrives during a period of regulatory activity at every level of the global BCI map. China elevated BCI to its 2026 Government Work Report (Inside BCI, 4 April) and issued Order 818 establishing a parallel commercial pathway for invasive BCI (Inside BCI, 8 May). The EU’s AI Act medical-device enforcement was delayed to 2028 on 7 May. CMS WISeR bifurcated US neuromodulation reimbursement (Inside BCI, 8 May). Vermont became the fifth US state to enact a neural rights statute on 18 May.

The BRAIN Initiative roadmap is the federal research-policy entry in this map. Where China is using industrial policy to coordinate state-funded research with commercial production, the US version remains operationally split: federal research policy via the BRAIN Initiative (which has invested more than $3.5 billion since 2014), federal reimbursement policy via CMS, federal regulatory policy via FDA, and state-by-state neural data privacy law. The Roadmap stays inside the research half and explicitly notes that downstream industry investment is required for translation. The Director’s Message, signed by Ngai and Adams, extends the framing further to “complex questions about autonomy, privacy, and potential uses of neurotechnology beyond medicine, requiring careful ethical oversight and input from society as a whole.” That political framing is the Director’s Message authors’ own, not the formal Roadmap’s.

What to watch

The first watch item is appropriations. The roadmap arrives during a period of leadership transition at NINDS (Adams is Acting Director, not permanent) and during broader budget pressure on US federal science agencies. The Roadmap’s own NeuroAI workshop plan explicitly defers some implementation steps “pending budget clarity.” Whether NeuroAI receives dedicated appropriations in the next funding cycle, or whether the domain remains a strategic priority without proportionate budget, will be the meaningful signal. The second watch item is the first round of Phase 1 NeuroAI data challenges and seed grants. Those will indicate which research groups and which institutional partners are positioned at the front of the federal NeuroAI cohort. The third watch item is whether industry BCI companies (Neuralink, Synchron, Paradromics, Precision Neuroscience, Blackrock) engage with the BRAIN Initiative through the formal Phase 3 cooperative agreement and public-private partnership pathway the Roadmap names, or whether the industry track remains operationally separate from federal research priorities.

Sources

• Inventing the Future of Neuroscience: A Shared Roadmap for the Next Decade (NINDS Director’s Message, 15 May 2026)
• Neuroscience Research Roadmap (Neuron, Cell Press, May 2026)
• NIH BRAIN Research Roadmap Innovation Domains: Detailed Scoping Plans (BRAIN Initiative, August 2025)
• BRAIN Initiative researchers ‘dream big’ amid shifts in leadership, funding (The Transmitter)
• BRAIN Initiative: Advancing Human Neuroscience and Precision Molecular Therapies for Transformative Treatments (NIH Grants)